AP2A1 Recombinant Monoclonal Antibody

AP2A1, also known as alpha1-adaptin, serves as a critical component of the AP-2 adaptor protein complex, which orchestrates clathrin-mediated endocytosis at the plasma membrane. This process is fundamental to receptor internalization, nutrient uptake, and synaptic vesicle recycling, making AP2A1 an essential target for researchers investigating membrane trafficking, signal transduction, and neurobiology.

This recombinant monoclonal antibody, clone 4D7, offers the reproducibility and consistency that demanding experimental workflows require. Generated against a synthetic peptide derived from human AP2A1, the antibody is produced using recombinant technology, ensuring sequence-defined specificity and eliminating the lot-to-lot variability often encountered with traditional hybridoma-derived antibodies. This reliability is particularly valuable for longitudinal studies or when establishing standardized protocols across research teams.

The antibody has been validated for immunofluorescence applications, with testing performed on HeLa cells demonstrating clear cytoplasmic staining patterns consistent with AP2A1's known localization at the plasma membrane and clathrin-coated pits. Working dilutions of 1:50 to 1:200 provide flexibility for optimization across different experimental conditions and imaging systems. The validation protocol employed standard fixation with 4% formaldehyde and blocking with normal goat serum, followed by overnight primary antibody incubation and detection with Alexa Fluor 488-conjugated secondary antibody.

Supplied in a glycerol-containing buffer optimized for long-term stability, this antibody supports research into endocytic pathways, receptor trafficking dynamics, and clathrin-dependent cellular processes. It represents a valuable tool for cell biologists exploring membrane dynamics and investigators studying how disrupted endocytosis contributes to disease states.